GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39247
Submission : 2023-12-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39247
Submission : 2023-12-06
Status : Active
Type : II
FINISHED DOSAGE FORMULATIONS
Drug : PHENYTOIN
Dosage Form : SUSPENSION; ORAL
Application Number : 89892
Country : US
Patented : No
Drug : SODIUM POLYSTYRENE SULFONATE
Dosage Form : SUSPENSION; ORAL, RECTAL
Application Number : 90590
Country : US
Patented : No
Drug : NAPROSYN
Dosage Form : SUSPENSION; ORAL
Application Number : 18965
Country : US
Patented : No
Drug : CLOBAZAM
Dosage Form : SUSPENSION; ORAL
Application Number : 208819
Country : US
Patented : No
Drug : E.E.S. 400
Dosage Form : TABLET; ORAL
Application Number : 61905
Country : US
Patented : No
Drug : ERYPED
Dosage Form : GRANULE; ORAL
Application Number : 50207
Country : US
Patented : No
Drug : E.E.S.
Dosage Form : GRANULE; ORAL
Application Number : 50207
Country : US
Patented : No
Drug : CLOBAZAM
Dosage Form : SUSPENSION; ORAL
Application Number : 213110
Country : US
Patented : No
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
Drug : TRI-LUMA
Dosage Form : CREAM; TOPICAL
Application Number : 21112
Country : US
Patented : No
Drug : SODIUM POLYSTYRENE SULFONATE
Dosage Form : SUSPENSION; ORAL, RECTAL
Application Number : 89049
Country : US
Patented : No
EXCIPIENTS BY APPLICATIONS